U.S. Food and Drug Administration (FDA) has approved Allergan’s Rhofade skin desease cream, a topical treatment of persistent facial erythema (redness) associated with rosacea in adults.
In two clinical trials, a once-daily application of Rhofade reduced persistent facial erythema related with rosacea through 12 hours. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29.
David Nicholson, Chief R&D Officer of Allergan said that Rhofade is the first and only alpha Aadrenoceptor agonist approved for persistent facial erythema associated with rosacea in adults.
The National Rosacea Society (NRS) estimates that approximately 16 million Americans are affected by rosacea.